Anna Balato
Naples, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 269 publications
Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies: An International Real-World Study.
Journal: International journal of dermatology
Published: July 02, 2026
Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis).
Journal: Journal of clinical medicine
Published: April 17, 2026
Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 11, 2026
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis.
Journal: Dermatology and therapy
Published: April 10, 2026
Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience.
Journal: Expert opinion on biological therapy
Published: April 01, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: March 17, 2026
Combined use of isotretinoin and secukinumab in pediatric Darier disease: a sustained clinical response.
Journal: Italian journal of dermatology and venereology
Published: March 16, 2026
Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area.
Journal: Dermatology and therapy
Published: March 11, 2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study.
Journal: Dermatology and therapy
Published: March 04, 2026
Psoriatic patients with cancer: a multicentric real-life study comparing Risankizumab and Apremilast.
Journal: Dermatology (Basel, Switzerland)
Published: March 04, 2026
Dupilumab as a targeted therapeutic strategy for Th2-driven cutaneous manifestations in Kimura disease.
Journal: Dermatology reports
Published: February 18, 2026
Treatment-associated phenotype switching between psoriasis and atopic dermatitis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 11, 2026
Last Updated: 09/26/2026